1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

07 Jul 2021
Admin
News Article

Glenmark To Conduct Phase Iii Trial Nasal Spray Meant To Treat Covid-19

Glenmark Pharmaceuticals Will Be Conducting A Phase Iii Trial On A Nitric Oxide Nasal Spray, Which It Claims Is Effective In Treatment Of Covid-19.The Company Had Sought Emergency Approval For Import And Marketing Of The Nasal Spray From The Drug Regulator Last Week. However, The Subject Expert Committee (Sec) Under The Drug Regulator Recommended Glenmark To Conduct The Phase Iii Trial.The Firm Presented Their Proposal For Grant Of Emergency Approval For Import And Marketing The Drug Product Before The Committee. After Detailed Deliberation, The Committee Recommended That The Firm Should Conduct Phase Iii Clinical Trial In Indian Patients And Accordingly, Clinical Trial Protocol Should Be Submitted For Review By The Committee,&Rdquo; The Minutes Of The Meeting.The Company Said That They Will Continue To Evaluate Various In-Licensing Opportunities Across Our Their Segments.The Company Said That They Will Continue To Lead Various In . We Have Always Led From The Front In The Fight Against The Covid19 Pandemic Which Is Demonstrated By The Strong Support Fabiflu Has Received From Doctors And Patients In The Treatment Of Mild To Moderate Covid19. We Are Exploring Various Partnerships Including The One With Sanotize Which Can Help In Protecting The Indian Population From The Sars-Cov-2 Virus And Reducing The Impact Of This Pandemic On Our Society&Rdquo;.The Nasal Spray Works By Killing The Virus Largely In The Upper Airways, Preventing It From Spreading To The Lungs.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!